The Pharma Tariff Deadline: 100 Percent or $14.5 Billion in New Plants

On April 2, 2026, the president signed a proclamation finding that patented pharmaceuticals and their ingredients are "essential to the United States' military and civilian healthcare" and setting a default 100 percent tariff on imports of them.▸ The Federal Register notice sets the tariff effective for a named list of companies (Annex III to the proclamation) starting July 31, 2026, and for every other company starting September 29, 2026. The rate a given shipment pays depends entirely on where it's from and whether its manufacturer has cut a deal — and drugmakers have already committed billions of dollars to plants in two states in what looks like a rush to be on the right side of that line.

The proclamation doesn't set one number.▸ It sets a schedule, keyed to where a drug is made and whether its manufacturer has struck a deal with the Commerce Department. Patented pharmaceuticals and associated ingredients on the proclamation's Annex I list face a 100 percent ad valorem duty by default. Companies that have — or are assessed as likely soon to have — an onshoring plan approved by the Secretary of Commerce pay 20 percent instead, a discount that itself expires: the rate rises to 100 percent on April 2, 2030 regardless of the plan's status. Products of the European Union, Japan, South Korea, and Switzerland/Liechtenstein get a flat 15 percent under separate country-level terms; the United Kingdom gets 10 percent, with a path to zero under a future pricing agreement. Generic drugs and their ingredients are excluded from the tariff entirely, "at this time," per the proclamation's own text. A further carve-out zeroes out the rate for orphan drugs, cell and gene therapies, plasma-derived products, fertility treatments, and a handful of other specialty categories the Secretary designates.

The proclamation states its own rationale plainly: citing FDA data, it puts import reliance for patented pharmaceutical products distributed domestically at approximately 53 percent as of 2025, and says reliance is worse further up the supply chain — only 15 percent of patented active pharmaceutical ingredients, by volume, are produced domestically for the U.S. market.▸ The tariff is built to close that gap by making the other 85 percent of API volume more expensive to keep importing.

Since March 2025, four drugmakers have announced new U.S. manufacturing plants for patented, branded products — biologics, monoclonal antibodies, and small-molecule drugs of exactly the kind the tariff targets — in Virginia and North Carolina.▸ None of the four companies' own announcements cites Section 232 by name; all of them frame the investment as supply-chain resilience or national-security-adjacent capacity, language that mirrors the proclamation's own justification. Pharmaceutical Commerce reported that across the industry, manufacturers were "committing to US manufacturing efforts as a way to avoid paying steep tariffs" — a framing from trade press covering the announcements, not a claim made by the companies themselves.

Eli Lilly committed $5 billion and 650 permanent jobs to an API and drug-product plant in Goochland County, Virginia, announced September 16, 2025.▸ AstraZeneca followed on October 9 with $4.5 billion and 600 direct jobs for two plants in Albemarle County, Virginia. Merck put $3 billion and more than 500 jobs into an expansion of its Elkton, Virginia site on October 20 — a facility that includes capacity for its top-selling drug Keytruda. Johnson & Johnson broke ground in Wilson, North Carolina in March 2025 on a $2 billion biologics facility with more than 500 permanent jobs. Combined, the four plants total $14.5 billion in pledged investment and more than 2,250 permanent jobs — against a tariff deadline that starts arriving in three weeks.

The four plant figures are each company's own announced commitment for that specific facility, not the company's broader multi-year U.S. investment total (several of the same companies have announced far larger figures, such as Eli Lilly's $50 billion multi-site pledge and AstraZeneca's $50 billion by 2030, which are not included in the $14.5 billion total above). "500+" job figures are the companies' own rounded public commitments, not precise headcounts.